{"filing":{"accession_number":"0001636282-26-000075","cik":"0001636282","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"syre-20260529.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/syre-20260529.htm"},"events":[{"id":7966,"run_id":6995,"accession_number":"0001636282-26-000075","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The Amendment expands the Field of the SPY003 License Agreement from inflammatory bowel disease to all therapeutic uses, subject to time-based dosing restrictions. This materially broadens the Company's development rights and commercial potential for SPY003, affecting the scope of its pipeline and strategic optionality. While not a traditional M\u0026A, restatement, or executive event, the expansion of licensed rights and removal of field restrictions is material to investors assessing the registrant's asset base and development strategy.","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3362,"accession_number":"0001636282-26-000075","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Amendment expands the Field of the SPY003 License Agreement from inflammatory bowel disease to all therapeutic uses, subject to time-based dosing restrictions. This materially broadens the Company's development rights and commercial potential for SPY003, affecting the scope of its pipeline and strategic optionality. While not a traditional M\u0026A, restatement, or executive event, the expansion of licensed rights and removal of field restrictions is material to investors assessing the registrant's asset base and development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:08:59.393555+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3362,"accession_number":"0001636282-26-000075","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Amendment expands the Field of the SPY003 License Agreement from inflammatory bowel disease to all therapeutic uses, subject to time-based dosing restrictions. This materially broadens the Company's development rights and commercial potential for SPY003, affecting the scope of its pipeline and strategic optionality. While not a traditional M\u0026A, restatement, or executive event, the expansion of licensed rights and removal of field restrictions is material to investors assessing the registrant's asset base and development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T03:08:59.393555+00:00","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-06-01"}]}